michigan hypertension core curriculum - State of Michigan
michigan hypertension core curriculum - State of Michigan
michigan hypertension core curriculum - State of Michigan
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
3. Singer GM, Izhar M, Black HR. Goal-oriented <strong>hypertension</strong> management: translating clinical<br />
trials to practice. Hypertension. Oct 2002;40(4):464-469.<br />
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management <strong>of</strong> Arterial<br />
Hypertension: The Task Force for the Management <strong>of</strong> Arterial Hypertension <strong>of</strong> the European<br />
Society <strong>of</strong> Hypertension (ESH) and <strong>of</strong> the European Society <strong>of</strong> Cardiology (ESC). J Hypertens.<br />
Jun 2007;25(6):1105-1187.<br />
5. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care<br />
patients is highly prevalent and poorly controlled. Am J Hypertens. Oct 2004;17(10):904-910.<br />
6. Weinberger MH. Salt sensitivity <strong>of</strong> blood pressure in humans. Hypertension. Mar 1996;27(3 Pt<br />
2):481-490.<br />
7. Wildman RP, Gu D, Muntner P, et al. Alcohol intake and <strong>hypertension</strong> subtypes in Chinese men.<br />
J Hypertens. Apr 2005;23(4):737-743.<br />
8. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects <strong>of</strong> alcohol reduction<br />
on blood pressure: a meta-analysis <strong>of</strong> randomized controlled trials. Hypertension. Nov<br />
2001;38(5):1112-1117.<br />
9. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant <strong>hypertension</strong> revisited: a comparison<br />
<strong>of</strong> two university-based cohorts. Am J Hypertens. May 2005;18(5 Pt 1):619-626.<br />
10. Carter BL, Lund BC, Hayase N, Chrischilles E. A longitudinal analysis <strong>of</strong> antihypertensive drug<br />
interactions in a Medicaid population. Am J Hypertens. May 2004;17(5 Pt 1):421-427.<br />
11. Fugh-Berman A. Herb-drug interactions. Lancet. Jan 8 2000;355(9198):134-138.<br />
12. Sowers JR, White WB, Pitt B, et al. The Effects <strong>of</strong> cyclooxygenase-2 inhibitors and nonsteroidal<br />
anti-inflammatory therapy on 24-hour blood pressure in patients with <strong>hypertension</strong>,<br />
osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. Jan 24 2005;165(2):161-168.<br />
13. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood<br />
pressure? A meta-analysis. Ann Intern Med. Aug 15 1994;121(4):289-300.<br />
14. Pavlicevic I, Kuzmanic M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and<br />
NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. Fall 2008;15(3):e372-382.<br />
15. W<strong>of</strong>ford MR, King DS, Wyatt SB, Jones DW. Secondary Hypertension: Detection and<br />
Management for the Primary Care Provider. J Clin Hypertens (Greenwich). Mar 2000;2(2):124-<br />
131.<br />
16. Yakovlevitch M, Black HR. Resistant <strong>hypertension</strong> in a tertiary care clinic. Arch Intern Med. Sep<br />
1991;151(9):1786-1792.<br />
17. Saelen MG, Prosch LK, Gudmundsdottir H, et al. Controlling systolic blood pressure is difficult in<br />
patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function.<br />
Blood Press. 2005;14(3):170-176.<br />
18. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control <strong>hypertension</strong>. N Engl J<br />
Med. Jul 27 2006;355(4):385-392.<br />
19. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med. Feb 8 2001;344(6):431-442.<br />
20. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence <strong>of</strong> primary<br />
aldosteronism in 199 patients referred with <strong>hypertension</strong>. Clin Exp Pharmacol Physiol. Apr<br />
1994;21(4):315-318.<br />
21. Douma S, Petidis K, Doumas M, et al. Prevalence <strong>of</strong> primary hyperaldosteronism in resistant<br />
<strong>hypertension</strong>: a retrospective observational study. Lancet. Jun 7 2008;371(9628):1921-1926.<br />
22. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism<br />
among black and white subjects with resistant <strong>hypertension</strong>. Hypertension. Dec 2002;40(6):892-<br />
896.<br />
23. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization <strong>of</strong> resistant<br />
<strong>hypertension</strong>: association between resistant <strong>hypertension</strong>, aldosterone, and persistent<br />
intravascular volume expansion. Arch Intern Med. Jun 9 2008;168(11):1159-1164.<br />
24. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease.<br />
NKFM & MDCH 233